Soraphen A enhances macrophage cholesterol efflux via indirect LXR activation and ABCA1 upregulation.

[1]  F. Sasse,et al.  The intriguing chemistry and biology of soraphens. , 2019, Natural product reports.

[2]  A. Atanasov,et al.  Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products , 2019, Pharmacological Reviews.

[3]  R. Sivamani,et al.  Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition , 2019, Science Translational Medicine.

[4]  Xi-Long Zheng,et al.  Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis. , 2019, Progress in lipid research.

[5]  C. Sirlin,et al.  Acetyl‐CoA Carboxylase Inhibitor GS‐0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  V. Dirsch,et al.  Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR. , 2018, Biotechnology advances.

[7]  R. Loomba,et al.  GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[8]  A. Atanasov,et al.  6‐Dihydroparadol, a Ginger Constituent, Enhances Cholesterol Efflux from THP‐1‐Derived Macrophages , 2018, Molecular nutrition & food research.

[9]  Emma L. Koppe,et al.  An unexpected link between fatty acid synthase and cholesterol synthesis in proinflammatory macrophage activation , 2018, The Journal of Biological Chemistry.

[10]  S. Yusuf,et al.  Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease , 2017, Circulation research.

[11]  S. Yusuf,et al.  Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. , 2017, Circulation research.

[12]  A. Bulmer,et al.  Bilirubin Decreases Macrophage Cholesterol Efflux and ATP‐Binding Cassette Transporter A1 Protein Expression , 2017, Journal of the American Heart Association.

[13]  M De Spirito,et al.  Fatty acid-related modulations of membrane fluidity in cells: detection and implications , 2016, Free radical research.

[14]  Xinyi Huang,et al.  Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats , 2016, Proceedings of the National Academy of Sciences.

[15]  J. Ruysschaert,et al.  Phosphatidylethanolamine Is a Key Regulator of Membrane Fluidity in Eukaryotic Cells* , 2015, The Journal of Biological Chemistry.

[16]  S. Zahler,et al.  Pharmacological targeting of membrane rigidity: implications on cancer cell migration and invasion , 2015 .

[17]  A. Daugherty,et al.  Recent Highlights of ATVB , 2016 .

[18]  M. P. Bourbeau,et al.  Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease. , 2015, Journal of medicinal chemistry.

[19]  Nataliya Gorinski,et al.  De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells , 2014, Nature Medicine.

[20]  Yanbo Yang,et al.  Cholesterol efflux from THP-1 macrophages is impaired by the fatty acid component from lipoprotein hydrolysis by lipoprotein lipase. , 2014, Biochemical and biophysical research communications.

[21]  Yutong Wang,et al.  ApoA-I or ABCA1 expression suppresses fatty acid synthesis by reducing 27-hydroxycholesterol levels. , 2014, Biochimie.

[22]  M. Passarelli,et al.  The impact of dietary fatty acids on macrophage cholesterol homeostasis. , 2014, The Journal of nutritional biochemistry.

[23]  P. Hopkins,et al.  Molecular biology of atherosclerosis. , 2013, Physiological reviews.

[24]  I. Schulman,et al.  Differential regulation of gene expression by LXRs in response to macrophage cholesterol loading. , 2013, Molecular endocrinology.

[25]  R. Bauer,et al.  Polyacetylenes from Notopterygium incisum–New Selective Partial Agonists of Peroxisome Proliferator-Activated Receptor-Gamma , 2013, PloS one.

[26]  Luciano Galdieri,et al.  Acetyl-CoA Carboxylase Regulates Global Histone Acetylation*♦ , 2012, The Journal of Biological Chemistry.

[27]  Zahi A Fayad,et al.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. , 2012, Circulation.

[28]  F. Ohsuzu,et al.  Proteasomal Inhibition Promotes ATP-Binding Cassette Transporter A1 (ABCA1) and ABCG1 Expression and Cholesterol Efflux From Macrophages In Vitro and In Vivo , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[29]  L. Olson,et al.  Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation. , 2011, Biochemical pharmacology.

[30]  Sebastian Munck,et al.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. , 2010, Cancer research.

[31]  M. Chamaillard,et al.  Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon , 2010, Proceedings of the National Academy of Sciences.

[32]  A. Gerding,et al.  Soraphen, an inhibitor of the acetyl‐CoA carboxylase system, improves peripheral insulin sensitivity in mice fed a high‐fat diet , 2009, Diabetes, obesity & metabolism.

[33]  B. Staels,et al.  Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. , 2009, Biochemical pharmacology.

[34]  Elina Ikonen,et al.  Cellular cholesterol trafficking and compartmentalization , 2008, Nature Reviews Molecular Cell Biology.

[35]  G. Chimini,et al.  ABCA1, from pathology to membrane function , 2007, Pflügers Archiv - European Journal of Physiology.

[36]  H. J. Harwood Jr,et al.  Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition , 2005 .

[37]  Liang Tong,et al.  A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. , 2004, Molecular cell.

[38]  E. Favari,et al.  Probucol Inhibits ABCA1-Mediated Cellular Lipid Efflux , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[39]  R. Müller,et al.  Myxobacteria: proficient producers of novel natural products with various biological activities--past and future biotechnological aspects with the focus on the genus Sorangium. , 2003, Journal of biotechnology.

[40]  R. Solà,et al.  HDL derived from the different phases of conjugated diene formation reduces membrane fluidity and contributes to a decrease in free cholesterol efflux from human THP-1 macrophages. , 2003, Biochimica et biophysica acta.

[41]  M. Moskowitz,et al.  Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. , 2001, Stroke.

[42]  S. Kliewer,et al.  Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  H Irschik,et al.  The soraphens: a family of novel antifungal compounds from Sorangium cellulosum (Myxobacteria). I. Soraphen A1 alpha: fermentation, isolation, biological properties. , 1994, The Journal of antibiotics.

[44]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[45]  B. Desvergne,et al.  RXRs: collegial partners. , 2014, Sub-cellular biochemistry.

[46]  I. Tabas.  Macrophage death and defective inflammation resolution in atherosclerosis , 2010, Nature Reviews Immunology.